Axentis Pharma is a specialty pharmaceutical company whose core competence is the combination of a fully patented, liposome-based drug delivery technology with already established and well-characterized therapeutic agents. Currently, the company exploits its drug delivery technology for the development of AX-TOBRA™, inhalable liposomal tobramycin, which is delivered directly to the site of infections via standard nebulizers.
|
|||
 |
|||
|
Welcome to Axentis Pharma
The company's lead product, AX-TOBRA™, is a clinical Ph 2 stage treatment for pulmonary infections in patients with cystic fibrosis. AX-TOBRA™ has a unique microbiological profile which sets it apart from other antibiotic formulations (including free tobramycin). The most recent orphan drug designation for AX-TOBRA™ relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients.
|
News:
 
2009-04-30
US FDA Orphan Designation: FDA grants orphan drug designation for liposomal tobramycin (ARB-CF0223)
read more
|
||
|
Fluidosomes™ (fluid liposomes)
Worldwide patents issued;
full freedom to operate - EU EMEA Orphan Drug designation
Pseudomonas infections in cystic fibrosis
Granted (March, 2006) +10 yrs market exclusivity in EU - US FDA Orphan Drug designation
Pseudomonas infections in cystic fibrosis
Granted (April, 2009) +7 yrs market exclusivity in USA - US FDA Orphan Drug designation
B. cepacia infections in cystic fibrosis
Granted (May, 2009) +7 yrs market exclusivity in USA |
Mechanism of Action
|
||
|
Meet us at
|
Documentation
|
||
|
© 2010 Axentis Pharma AG Limmatquai 138, 8001 Zurich phone: +41 44 202 7878 board@axentispharma.com
|
|||
